Precision Biosciences Inc logo

DTIL

Precision Biosciences Inc

$1.94

Earnings Summary

Revenue
$3.32Mn
Net Profits
$-28.17Mn
Net Profit Margins
-849.2%

Highlights

Revenue:

Precision Biosciences Inc’s revenue fell -79.71% since last year same period to $3.32Mn in the Q1 2022. On a quarterly growth basis, Precision Biosciences Inc has generated -47.67% fall in its revenue since last 3-months.

Net Profits:

Precision Biosciences Inc’s net profit fell -50.72% since last year same period to $-28.17Mn in the Q1 2022. On a quarterly growth basis, Precision Biosciences Inc has generated -26.37% fall in its net profits since last 3-months.

Net Profit Margins:

Precision Biosciences Inc’s net profit margin fell -642.87% since last year same period to -849.2% in the Q1 2022. On a quarterly growth basis, Precision Biosciences Inc has generated -141.5% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Precision Biosciences Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.41
EPS Estimate Current Year
-0.41

Highlights

EPS Estimate Current Quarter:

Precision Biosciences Inc’s earning per share (EPS) estimates for the current quarter stand at -0.41 - a 24.07% jump from last quarter’s estimates.

EPS Estimate Current Year:

Precision Biosciences Inc’s earning per share (EPS) estimates for the current year stand at -0.41.

Key Ratios

Key ratios of the Precision Biosciences Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.46
Return on Assets (ROA)
-0.24
Return on Equity (ROE)
-0.91
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Precision Biosciences Inc’s earning per share (EPS) fell -39.39% since last year same period to -0.46 in the Q1 2022. This indicates that the Precision Biosciences Inc has generated -39.39% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Precision Biosciences Inc’s return on assets (ROA) stands at -0.24.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Precision Biosciences Inc’s return on equity (ROE) stands at -0.91.

Dividend Per Share (DPS):

Precision Biosciences Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-0.54
-0.46
14.81%

Company Information

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple 'off-the-shelf' CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist.

Organisation
Precision Biosciences Inc
Headquarters
Durham, North Carolina, United States
Employees
231
Industry
Biotechnology
CEO
Matthew Kane